Satlin Andrew 4
4 · Intra-Cellular Therapies, Inc. · Filed Jan 10, 2020
Insider Transaction Report
Form 4
Satlin Andrew
EVP and Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2020-01-08+22,911→ 22,911 total - Exercise/Conversion
Restricted Stock Units
2020-01-08−22,911→ 45,824 total→ Common Stock (22,911 underlying) - Sale
Common Stock
2020-01-09$26.16/sh−11,573$302,750→ 11,338 total
Footnotes (5)
- [F1]Restricted stock units convert into common stock on a one-for-one basis.
- [F2]The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 19, 2019. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.85 to $26.81, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F4]Each restricted stock unit represents a contingent right to receive one share of common stock.
- [F5]On January 8, 2019, the reporting person was granted 68,735 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.